医学
肺结核
内科学
重症监护医学
结核病诊断
梅德林
外科
儿科
流行病学
结核分枝杆菌
结核病治疗
直接观察疗法
医学检查
抗菌剂
对偶(语法数字)
活动性肺结核
家庭医学
急诊医学
入射(几何)
作者
Sandra Pérez‐Recio,Maria D. Grijota‐Camino,Jordi Guardiola,Xavier Juanola,Jaime Notario,Xavier Solanich,Francisco Rodríguez‐Moranta,Joan Miquel Nolla Solé,Rosa Fornons‐Servent,Elena Sánchez-Pastor,Maria J Luque,Núria Sabé,Miguel Santín,for the Prevention of Tuberculosis Associated with Biologic Therapies Study Group,Alexandra Ruiz‐Cerulla,Javier Narváez,Carmen Gómez‐Vaquero,Laura Berbel-Arcobé,Cristina Trapero
摘要
BACKGROUND: This study builds on previous evidence to assess the risk of tuberculosis (TB) in patients treated with biologic therapies (BioT), the role of the interferon-γ-release assay (IGRA) QuantiFERON-TB (QFT) Gold as a stand-alone screening test, and whether periodic re-testing is warranted for patients with a negative pre-BioT screening. METHODS: A total of 1368 patients starting BioT were screened for TB infection using 4 screening strategies over 4 consecutive periods: (1) 2-step tuberculin skin test (TST); (2) 2-step TST plus QFT Gold In-Tube; (3) single-step TST plus QFT Gold In-Tube; and (4) QFT Gold In-Tube (or QFT Gold Plus) alone. All patients with TB infection were offered preventive therapy. RESULTS: TB infection was diagnosed in 327 (23.9%) patients (40.8%, 39.5%, 25.3%, and 14.8% in the first, second, third, and fourth periods, respectively; P = .000). The adjusted odds ratios (ORs) with respect to the first period were 0.89 (95% CI, .55-1.44), 0.49 (95% CI, .33-.73), and 0.23 (95% CI, .15-.36) for the second, third, and fourth periods, respectively. During follow-up, 11 patients (0.8%) developed TB. The probability of remaining TB-free after 11 years of BioT exposure was 99.1%, with no significant differences between screening periods (P = .372). All TB cases in patients with negative baseline screening occurred within the first year of BioT exposure. CONCLUSIONS: Although BioT-associated TB can be significantly reduced, it is not completely preventable. Neither dual testing nor periodic systematic re-screening for TB infection is warranted after a negative pre-BioT test.
科研通智能强力驱动
Strongly Powered by AbleSci AI